Substituted E-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones with Antitumor Activity. In Depth Study of the Effect on Growth of Breast Cancer Cells
摘要:
The synthesis of new substituted E-3-(3-indolylmethylene)-1,3-dihydroindo1-2-ones is reported. The antitumor activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. Structure activity relationships are discussed. The action of selected compounds was investigated in MCF-7 breast cancer cells. The ability of these derivatives to inhibit cellular proliferation was accompanied by increased level of p53 and its transcriptional targets p21 and Bax, interference in the cell cycle progression with cell accumulation in the G2/M phase, and activation of apoptosis.
TargetingG-quadruplex structures is currently viewed as a promising anticancer strategy. Searching for potent and selective G-quadruplex binders, here we describe a small series of new monohydrazone derivatives designed as analogues of a lead which was proved to stabilize G-quadruplex structures and increase R loop levels in human cancer cells. To investigate the G-quadruplex binding properties of
[EN] INDOLE-3-METHANAMINES USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS
申请人:THE UPJOHN COMPANY
公开号:WO1992007829A1
公开(公告)日:1992-05-14
(EN) The present invention provides novel compounds which are useful in the treatment of NIDDM, obesity, hypertension or atherosclerosis. This invention encompasses a compound of formula (I), wherein R1-R6 represent a variety of substituents, and a method of treatment of the above conditions.(FR) Nouveaux composés utilisés dans le traitement du diabète sucré indépendant de l'insuline (NIDDM), de l'obésité, de l'hypertension ou de l'athérosclérose. L'invention comprend un composé de formule (I), dans laquelle R1-R6 représentent toute une variété de substituants, ainsi qu'un procédé de traitement des conditions pathologiques susmentionnées.